683 Capital Management LLC Increases Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

683 Capital Management LLC grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 16.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 102,000 shares of the biotechnology company's stock after purchasing an additional 14,778 shares during the period. Sarepta Therapeutics comprises 0.8% of 683 Capital Management LLC's portfolio, making the stock its 26th largest holding. 683 Capital Management LLC owned about 0.11% of Sarepta Therapeutics worth $12,402,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Manchester Capital Management LLC boosted its holdings in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB boosted its position in shares of Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 156 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in Sarepta Therapeutics in the fourth quarter valued at about $36,000. Steward Partners Investment Advisory LLC raised its position in Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 194 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in Sarepta Therapeutics by 95.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock worth $54,000 after purchasing an additional 216 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock traded down $9.72 during midday trading on Wednesday, hitting $37.03. 11,966,731 shares of the company traded hands, compared to its average volume of 1,535,074. The firm's fifty day moving average price is $70.87 and its 200-day moving average price is $102.57. The stock has a market cap of $3.64 billion, a price-to-earnings ratio of 29.67 and a beta of 0.85. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a 12 month low of $36.75 and a 12 month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The business had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. During the same quarter in the prior year, the business earned $0.73 earnings per share. The firm's quarterly revenue was up 80.2% on a year-over-year basis. As a group, sell-side analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on the company. HC Wainwright decreased their price target on Sarepta Therapeutics from $75.00 to $40.00 and set a "neutral" rating on the stock in a research note on Wednesday. Guggenheim decreased their price target on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating on the stock in a research note on Wednesday. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research report on Wednesday, March 19th. Morgan Stanley decreased their price objective on Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating on the stock in a research report on Wednesday. Finally, The Goldman Sachs Group dropped their target price on Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating for the company in a research report on Wednesday. Six investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $138.35.

Insider Buying and Selling

In other news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.